A Phase 3 interventional study of Metronidazole and Gel vehicle in Vaginal Infection, sponsored by Curatek Pharmaceuticals, LLC. Completed at 35 sites in United States. Open to female participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2020-07-27.
Sponsored by Curatek Pharmaceuticals, LLC · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Vaginitis with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Vaginitis · United States.
Among the 38 studies in Vaginitis with a site in United States, this one is the 13th largest by enrollment of the 33 interventional ones that give a count, is one of 5 that started in 2015, is one of 8 in phase 3, and was the 17th registered.
98 studies on the registry are indexed under Vaginitis; 12 are open to participants now.
Browse Vaginitis studies →4 of the 38 studies in Vaginitis with a site in United States are open now. Recruiting first, the newest first:
Nanopath, Inc · Sites in United States
Ages 18+ · Women only
University of Virginia · Sites in United States
Ages 18+ · Women only
Albert Einstein College of Medicine · Sites in United States
Ages 40–70 · Women only · Healthy volunteers
Atlantic Health System · Sites in United States
Ages 18+ · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Vaginitis studies recruiting now, 2 set no upper age limit and 3 stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 12 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 8 · Phase 4 4
First in 1999; this study’s year is marked. 5 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 204 is above the median of 108 across 71 interventional studies indexed under Vaginitis.
Median enrollment 77 across the 33 interventional studies, 299 across the 5 observational. Of the 27 that completed or were terminated, 12 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 38 have an industry lead sponsor. The 10 most frequent:
Curatek Pharmaceuticals, LLC is the lead sponsor of 3 studies on the registry; none are open to participants now.
Curatek Pharmaceuticals, LLC has 3 studies filed under Vaginitis — fewer than ten, so there is no comparison to draw.
1 of the studies in Vaginitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07607470Nanopath, IncLarge Algorithm Setting and Validation Study | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 38 studies in Vaginitis with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of metronidazole gel in the treatment of vaginal infections.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One applicator full at bedtime
Drug: Metronidazole
One applicator full at bedtime
Drug: Gel vehicle
Clinical Cure as Assessed by the Investigator at the Test-of-cure Visit
The percentage of participants with clinical cure in each arm was compared. Clinical cure of bacterial vaginosis is defined as 1. discharge has returned to normal/physiologic, 2. the whiff test is negative for any amine "fishy" odor, 3. the saline wet mount is \<20% clue cells
Time frame: 7-14 days after beginning treatment
Improvement of BV Clue Cells
Clue cells on wet mount were assessed and categorized as absent (\<20%) or present (\>=20%). Absence of clue cells is associated with improvement. The comparison was for percentage between arms for clue cells absent (\<20%).
Time frame: 7-14 days after beginning treatment
Microbiologic Improvement/Cure
For bacterial vaginosis (BV), Gram stain Nugent scores are catergized as normal (0 to 3), intermediate (4 to 6) or BV (7 to 10). Normal scores are associated with BV microbiologic cure. The percentage of participants with normal scores were compared between treatments.
Time frame: 7-14 days after beginning treatment
Number of Participants Reporting Complete Resolution of Symptoms by Test of Cure Visit
Subjects reported if symptoms completely resolved and the date of resolution. The percentage of participants reporting complete resolution of symptoms was compared between arms.
Time frame: 7-14 days after beginning treatment
Number of Participants With Treatment Emergent Adverse Events
Adverse events were collected at study visits, from subject diaries and from spontaneous reports
Time frame: Any time during study participation (up to 30 days)
| Milestone | Metronidazole Vaginal Gel | Gel Vehicle |
|---|---|---|
| Started | 102 | 102 |
| Completed | 76 | 83 |
| Not completed | 26 | 19 |
| Withdrew: Normal gram stain at baseline | 13 | 10 |
| Withdrew: Positive for std at baseline | 7 | 4 |
| Withdrew: Lost to follow-up | 6 | 5 |
The percentage of participants with clinical cure in each arm was compared. Clinical cure of bacterial vaginosis is defined as 1. discharge has returned to normal/physiologic, 2. the whiff test is negative for any amine "fishy" odor, 3. the saline wet mount is \<20% clue cells
| Participants | Metronidazole Vaginal Gel | Gel Vehicle |
|---|---|---|
| Clinical Cure as Assessed by the Investigator at the Test-of-cure Visit | 47 | 18 |
Clue cells on wet mount were assessed and categorized as absent (\<20%) or present (\>=20%). Absence of clue cells is associated with improvement. The comparison was for percentage between arms for clue cells absent (\<20%).
| Participants | Metronidazole Vaginal Gel | Gel Vehicle |
|---|---|---|
| Clue cells absent | 52 | 19 |
| Clue cells present | 17 | 58 |
| Data missing | 7 | 6 |
For bacterial vaginosis (BV), Gram stain Nugent scores are catergized as normal (0 to 3), intermediate (4 to 6) or BV (7 to 10). Normal scores are associated with BV microbiologic cure. The percentage of participants with normal scores were compared between treatments.
| Participants | Metronidazole Vaginal Gel | Gel Vehicle |
|---|---|---|
| Normal Nugent score | 38 | 7 |
| Intermediate Nugent score | 16 | 11 |
| BV Nugent score | 15 | 59 |
| Not taken | 7 | 6 |
Subjects reported if symptoms completely resolved and the date of resolution. The percentage of participants reporting complete resolution of symptoms was compared between arms.
| Participants | Metronidazole Vaginal Gel | Gel Vehicle |
|---|---|---|
| Number of Participants Reporting Complete Resolution of Symptoms by Test of Cure Visit | 43 | 32 |
Adverse events were collected at study visits, from subject diaries and from spontaneous reports
| Participants | Metronidazole Vaginal Gel | Gel Vehicle |
|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events | 42 | 31 |
Collected over Adverse events were collected over the entire course of the study (up to 30 days after beginning treatment).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Metronidazole Vaginal Gel | 0/96 (0%) | 0/96 (0%) | 25/96 (26%) |
| Gel Vehicle | 0/97 (0%) | 0/97 (0%) | 10/97 (10.3%) |
| Event | Metronidazole Vaginal Gel | Gel Vehicle |
|---|---|---|
| Vulvovaginal pruritisReproductive system and breast disorders | 8/96 | 6/97 |
| Vulvovaginal candidiasisInfections and infestations | 7/96 | 1/97 |
| Vulvovaginal mycotic infectionInfections and infestations | 5/96 | 1/97 |
| HeadacheNervous system disorders | 5/96 | 2/97 |
modified intent-to-treat (mITT) population includes all subjects randomized to treatment and administered at least one dose of study drug. In addition, subjects must have a Nugent score of 4 or more on Baseline visit Gram stain slide.
| Age, Continuous(years) | Metronidazole Vaginal Gel | Gel Vehicle | Total |
|---|---|---|---|
| Mean | 33.1 ± 8.76 | 35.8 ± 10.48 | 34.5 ± 9.76 |
| Sex: Female, Male(Participants) | Metronidazole Vaginal Gel | Gel Vehicle | Total |
|---|---|---|---|
| Female | 76 | 83 | 159 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Metronidazole Vaginal Gel | Gel Vehicle | Total |
|---|---|---|---|
| Hispanic or Latino | 9 | 9 | 18 |
| Not Hispanic or Latino | 67 | 74 | 141 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Metronidazole Vaginal Gel | Gel Vehicle | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 47 | 45 | 92 |
| White | 25 | 32 | 57 |
| More than one race | 3 | 3 | 6 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Metronidazole Vaginal Gel | Gel Vehicle | Total |
|---|---|---|---|
| United States | 76 | 83 | 159 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2015 to primary completion in Jun 2017, 24 months.
Results were first posted in Jul 2020, 3 years 1 month after primary completion. A results delay was requested in Jun 2018.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metronidazole
Curatek Pharmaceuticals, LLC